HUMAN GENOME SCIENCES INC 4
4 · HUMAN GENOME SCIENCES INC · Filed Aug 1, 2012
Insider Transaction Report
Form 4
Bateson Susan D.
Senior Vice President
Transactions
- Disposition to Issuer
Employee Stock Option - Right to Buy
2012-07-30$14.25/sh−64,304$916,332→ 0 totalExercise: $4.92Exp: 2018-03-10→ Common Stock (64,304 underlying) - Disposition to Issuer
Employee Stock Option - Right to Buy
2012-07-30$14.25/sh−14,779$210,601→ 0 totalExercise: $10.62Exp: 2017-03-10→ Common Stock (14,779 underlying) - Disposition from Tender
Common Stock
2012-07-30$14.25/sh−62,270$887,348→ 0 total - Disposition to Issuer
Employee Stock Option - Right to Buy
2012-07-30$14.25/sh−67,997$968,957→ 0 totalExercise: $0.52Exp: 2019-03-10→ Common Stock (67,997 underlying) - Disposition to Issuer
Employee Stock Option - Right to Buy
2012-07-30$14.25/sh−2,120$30,210→ 0 totalExercise: $10.89Exp: 2016-03-14→ Common Stock (2,120 underlying) - Disposition to Issuer
Employee Stock Option - Right to Buy
2012-07-30$14.25/sh−108,000$1,539,000→ 0 totalExercise: $8.23Exp: 2022-03-10→ Common Stock (108,000 underlying) - Disposition to Issuer
Employee Stock Option - Right to Buy
2012-07-30$14.25/sh−49,354$703,295→ 0 totalExercise: $12.56Exp: 2015-01-17→ Common Stock (49,354 underlying) - Disposition to Issuer
Employee Stock Option - Right to Buy
2012-07-30$14.25/sh−76,923$1,096,153→ 0 totalExercise: $12.38Exp: 2013-12-10→ Common Stock (76,923 underlying)
Footnotes (7)
- [F1]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $83408.26 representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc.These options vested automatically upon consummation of the tender offer on July 30, 2012.
- [F2]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $53,647.77, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc.These options vested automatically upon consummation of the tender offer on July 30, 2012.
- [F3]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $599,956.32, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc.These options vested automatically upon consummation of the tender offer on July 30, 2012.
- [F4]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $933,598.81 representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc.These options vested automatically upon consummation of the tender offer on July 30, 2012.
- [F5]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $650,160.00, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc.These options vested automatically upon consummation of the tender offer on July 30, 2012.
- [F6]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $7,123.20 representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc.These options vested automatically upon consummation of the tender offer on July 30, 2012.
- [F7]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $143,846.01, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc. These options vested automatically upon consummation of the tender offer on July 30, 2012.